BOCA RATON, Fla., April 27, 2017,/PRNewswire/ — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), announced today that management will hold a conference call beginning at 4:30 p.m. Eastern Time on Thursday, May 4, 2017, to discuss the financial results for the first quarter of 2017. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
To access the conference call, the dial-in numbers are 1-877-870-4263 (U.S. Toll-Free), 1-412-317-0790 (International) and 1-855-669-9657 (Canada Toll-Free). Please ask the operator to be connected to the Sensus Healthcare call.
Following the conclusion of the conference call, a replay will be available through May 11, 2017, and can be accessed by dialing 1-877-344-7529 (U.S. Toll-Free), 1-412-317-0088 (International), and 1-855-669-9658 (Canada Toll-Free). All listeners should provide the replay passcode 10106354. The call will also be archived on the Company website for a time at https://www.sensushealthcare.com
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For further information, please visit https://www.sensushealthcare.com
Kim Sutton Golodetz
SOURCE Sensus Healthcare